Zai Lab Limited/ US98887Q1040 /

10/4/2023 4:09:12 PM	Chg. -0.69	Volume	Bid4:09:38 PM	Ask4:09:38 PM	High	Low
22.76USD	-2.94%	1,823 Turnover: 41,700.69	22.70Bid Size: 200	22.83Ask Size: 256	23.14	22.75

GlobeNewswire 3/23/2022 Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on Marc...

GlobeNewswire 3/22/2022 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited ...

GlobeNewswire 3/21/2022 Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gyne...

GlobeNewswire 3/16/2022 (ZLAB) Alert: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading ZLAB Class Act...

GlobeNewswire 3/15/2022 Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

GlobeNewswire 3/14/2022 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

GlobeNewswire 3/1/2022 Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

GlobeNewswire 2/17/2022 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

GlobeNewswire 2/15/2022 Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

GlobeNewswire 2/7/2022 Zai Lab Announces Upcoming Presentation at February Investor Conference

GlobeNewswire 1/12/2022 Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor ...

GlobeNewswire 12/29/2021 Zai Lab Announces Upcoming Presentations at January Investor Conferences

GlobeNewswire 12/22/2021 Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Ne...

GlobeNewswire 12/18/2021 Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgar...

GlobeNewswire 12/16/2021 China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...

GlobeNewswire 12/16/2021 China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Commu...

GlobeNewswire 12/3/2021 Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for F...

GlobeNewswire 11/30/2021 Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-...

GlobeNewswire 11/23/2021 Zai Lab Announces Upcoming Presentations at December Investor Conferences

GlobeNewswire 11/22/2021 Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

GlobeNewswire 11/16/2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...

GlobeNewswire 11/15/2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...

GlobeNewswire 11/11/2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...

GlobeNewswire 11/9/2021 Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates

GlobeNewswire 11/9/2021 Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 a...